Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GEN1107

Monoclonal antibody · developed by Genmab

Phase 1/2 Most advanced trial (none active)
GMAB Developer
1 Registered trials

What is GEN1107?

GEN1107 is a drug studied in endometrial cancer, ovarian cancer, triple negative breast cancer, gastroesophageal cancer, non-small cell lung cancer, and urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Oncology
Developer
Genmab (GMAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06171789 Phase 1/2 Endometrial Cancer Terminated GMAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerGastroEsophageal CancerNon-small Cell Lung CancerOvarian CancerTriple Negative Breast CancerUrothelial Carcinoma

More from Genmab

Follow GMAB, the company behind GEN1107

See GMAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GMAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.